北京亚博yabo官网科技发展有限公司(Excellence Future International Consulting Co. Ltd.)于2002年成立，是专注于为制药企业提供临床试验全过程专业服务的合同研究组织（CRO）。成立至今已承接了六百余项新药、器械及上市后药品的临床研究项目（含CRC项目），专业涉及呼吸、肿瘤、骨科、心血管、儿科、精神、消化、麻醉等多个领域，几乎涵盖整个医学细分学科。截止2018年底，共承接1.1类化学创新药12项，化学仿制药60余项，中药新药80余项，上市后中药再评价项目近百项。合作的研究中心达600余家，遍布全国25个省市自治区。公司下设卓越天使、卓越同舟两个子公司及医学中心、数据管理中心、项目促进中心、项目指挥中心、质控中心、商务中 心、药物警戒中心等业务部门，同时，在上海、广州、武汉、成都等15个核心城市设有分支机构。2019年公司总人数已超500人。
Founded in 2002, Excellence Future International Consulting Co. Ltd. is a contract research organization (CRO) dedicated to providing professional services of clinical trials whole process for pharmaceutical companies. Since its establishment, the company has undertaken more than 800 clinical research projects (including CRC projects) for new drugs, medical devices and post-marketing drugs, specialized in respiratory, oncology, orthopedics, cardiovascular, pediatric, mental, digestive, anesthetic and other fields, almost covering the entire medical subdivision discipline. By the end of 2018, it had undertaken 12 projects of innovated chemical drug, more than 60 projects of chemical generic drug, around 80 new Chinese medicines, and nearly 100 post-marketing ruation projects of Chinese medicine. There are more than 600 research centers in cooperation with Excellence Future distributed in 27 provinces, municipalities and autonomous regions all over the country. The company owns two subsidiaries: Excellence Angel and Excellence Create, and other functional departments like: medical center, data management center, project promotion center, project command center, quality control center, business center, pharmacovigilance center etc. At the same time, there are branches in 15 core cities such as Shanghai, Guangzhou, Wuhan, Chengdu etc. The total number of the company’s employee exceeds 500 in 2019.
Over the years, the company, committed to provide for enterprises "one-stop, full coverage of the drug life cycle" professional services, has established strategic partnership with dozens of domestic and foreign companies and research institutes. After nearly 20 years of development, The company's business has not only expanded from clinical CRO to SMO and preclinical CRO business, but also have formed unique characteristics in important links of the different stages of drug development: prescription screening, process validation, new drug declaration and approval, early intervention of innovative drugs, preclinical research, clinical trials, registration, risk management planning, and post-marketing academic promotion, top-level design, project declaration, and cultivation of main project. Relied on standardized process regulations, rich operational experience, complete quality control system, extensive expert resources, stable project management and execution team, the company has been recognized as one of the top CRO companies in China thanks to its integrity and professionalism.